SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
Link address : https://www.prnewswire.com/news-releases/sillajen-and-lees-pharmaceutical-announce-first-patient-enrolled-in-the-phocus-trial-in-china-phase-3-clinical-trial-for-oncolytic-immunotherapy-pexa-vec-in-liver-cancer-300705590.html
Targeting, Attacking, and Eradicating Cancers®
